| abstract |
The present invention is useful for the treatment of cardiac disorders, including systolic dysfunction, dilated cardiomyopathy (DCM), heart failure with reduced ejection fraction (HFrEF), and conditions associated with left ventricular and/or right ventricular systolic dysfunction or systolic reserve ( R )-4-(1-((3-(difluoromethyl)-1-methyl-1H-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-N-(isoxazole-3 Novel polymorphs of -yl)piperidine-1-carboxamide (I-491) are provided. Synthesis and characterization of polymorphs, as well as methods of treating systolic dysfunction, DCM, HFrEF, and other forms of heart disease are also described. |